Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potential interaction between itraconazole and clarithromycin.

B Auclair1, S E Berning, G A Huitt

  • 1Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, University of Colorado, Denver 80206, USA.

Pharmacotherapy
|December 22, 1999
PubMed
Summary

This study investigated drug interactions between clarithromycin and itraconazole in HIV-negative patients with Mycobacterium avium complex and aspergillosis. The findings suggest these antifungals can be safely co-administered, despite potential pharmacokinetic changes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pretomanid dosing and pharmacokinetics in patients with TB in a high-resource setting.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial.

The Journal of infectious diseases·2025
Same author

Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB.

IJTLD open·2024
Same author

Therapeutic drug monitoring for isoniazid and rifampicin exposure.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

Clinical standards for the management of adverse effects during treatment for TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Drug Interactions

Background:

  • Pulmonary Mycobacterium avium complex (MAC) and aspergillosis are opportunistic infections.
  • Treatment often involves clarithromycin for MAC and azole antifungals for aspergillosis.
  • Drug-drug interactions can affect treatment efficacy and safety.

Observation:

  • Three HIV-negative patients with MAC and aspergillosis received clarithromycin and itraconazole.
  • All patients exhibited increased clarithromycin concentrations and altered metabolite ratios.
  • No clinical adverse events were reported during treatment.

Findings:

  • A potential pharmacokinetic interaction between clarithromycin and itraconazole was observed.
  • The interaction is hypothesized to involve cytochrome P450 3A4 enzyme activity.

Related Experiment Videos

  • Bidirectional interaction effects cannot be excluded.

    • Implications:

    • Clarithromycin and itraconazole may be safely co-administered when clinically indicated.
    • Further research is needed to fully elucidate the clinical significance of this interaction.
    • This finding has implications for managing co-infections in immunocompromised patients.